Roche reports 1Q13 sales of new cancer drugs

Roche (SIX:ROG; OTCQX:RHHBY) reported 1Q13 earnings on Thursday, including sales for its two newest drugs for HER2-positive metastatic breast cancer. The pharma recorded sales of CHF18 million ($19.2 million) for Kadcyla ado-trastuzumab emtansine ( T-DM1), which the pharma launched in the U.S. in February; and CHF50 million ($53.5 million) in worldwide 1Q13 sales for Perjeta pertuzumab, which Roche launched in the EU in March and in the U.S. last June. ...